“This newly available treatment may help reduce the risk of disease recurrence, progression and death in resectable NSCLC when given before surgery," said Dr Meredith Edwards, the medical director of Bristol Myers Squibb Australia.
First immunotherapy-based neoadjuvant treatment for resectable NSCLC now funded via the PBS
August 1, 2024 Latest NewsBioPharmaLatest Video
New Stories
-
Amplia announces capital raise to support the completion of Phase 2a ACCENT tr
October 30, 2024 - - Australian Biotech -
Priceline Pharmacy launches a refreshed brand strategy
October 30, 2024 - - Latest News -
Vaccine procurement and rollout was slow, but reduced the number of deaths
October 30, 2024 - - Latest News -
Boehringer Ingelheim leader promoted to global role
October 30, 2024 - - Latest News -
At least this means the industry will never again take lectures on these issues
October 29, 2024 - - Latest News -
Decisions taken during the caretaker period are governed by a formal convention
October 29, 2024 - - Latest News -
Community pharmacy leads nationwide transformation of women’s health services
October 29, 2024 - - Latest News